CData Launches Databricks Integration Accelerator to Simplify and Accelerate Enterprise Data Integration
Purpose-built solution reduces data pipeline complexity and accelerates integration across hybrid and multi-cloud Databricks environments
CHAPEL HILL, N.C., June 11, 2025 /PRNewswire/ -- CData Software, a leading provider of data connectivity and integration solutions, today announced the launch of the CData Databricks Integration Accelerator, a new solution purpose-built to simplify and expedite enterprise data integration for Databricks environments. By eliminating traditional bottlenecks in data pipeline development, the Accelerator can reduce integration timelines by as much as 90%, helping organizations unlock insights faster and fully realize the potential of their Databricks Lakehouse investments.
The Databricks Lakehouse Platform combines data warehousing and AI with a unified architecture that supports real-time analytics and machine learning workflows. Yet, many enterprises encounter friction when integrating data from disparate systems due to the fragmented nature of legacy ETL tools and the need to support hybrid environments, including on-premises infrastructure and multi-cloud deployments. The CData Databricks Integration Accelerator mitigates these challenges by offering a no-code framework for building scalable ingestion pipelines, simplifying transformation tasks, and ensuring compliance with data governance standards like Unity Catalog.
"Integrating enterprise data into Databricks often requires extensive custom code and manual configuration, which can introduce delays and increase maintenance overhead," said Manish Patel, Chief Product Officer at CData. "Our Integration Accelerator eliminates those inefficiencies by providing prebuilt connectors, automated pipeline orchestration, and real-time data availability, enabling teams to operationalize data faster and focus on driving value through analytics and AI."
Overview of Databricks Solution Toolkits
The CData Databricks Integration Accelerator includes four purpose-built toolkits designed to enhance data integration capabilities:
Delta Lake Integration Toolkit: Enable no-code data ingestion into Delta Lake with Change Data Capture (CDC) from over 270 sources. This toolkit also facilitates live data access into sales, marketing, financial, and other business systems via Databricks Lakehouse Federation, ensuring full governance through Unity Catalog.
Delta Live Tables (DLT) Extension Toolkit: Expand DLT connectivity to all business applications, providing a unified SQL data model via Databricks Spark for simplified integration. The toolkit includes out-of-the-box authentication and pagination support for any API, along with server-side pushdown for optimal performance.
Databricks-Microsoft Connectivity Toolkit: Leverage standards-based connectivity between Databricks and Microsoft ecosystems, enabling native integration capabilities with SSAS, SSRS, SSIS, and more. The toolkit ensures performant live connectivity into Databricks from any application while maintaining complete Unity Catalog compatibility.
Agentic Data Pipelines Toolkit: Supercharge agentic workloads with CData's automated data ingestion capabilities, enabling true programmatic ingest into serverless PostgreSQL, fully compatible with Databricks serverless Postgres deployments. The toolkit provides instant data availability for AI agents with automated pipelines from any enterprise data source into Databricks serverless Postgres, programmatic orchestration to build and modify data pipelines via code, and real-time processing to integrate data from any source on-the-fly with CDC.
"Everyone needs a good way to load data into their data lake," said Eric Newcomer, CTO and Principal Analyst, Intellyx. "CData has been developing and delivering a broad and deep set of data connectors for more than a decade. Now, Databricks users can leverage not only the proven CData suite of connectors, but also the integration toolkits built on top of them, including SQL data models, Microsoft-specific connections, and MCP servers for AI agent automations."
Customer Success: NJM Insurance
NJM Insurance, a leading provider of personal and commercial insurance, leveraged the CData Databricks Integration Accelerator to transform their marketing analytics. By replacing code-intensive ETL processes with CData's no-code solution, NJM reduced integration build time by 90% and saved 66% on project costs. This enabled faster insights into customer acquisition costs and lifetime value, driving better decision-making across the organization. "With CData, we were able to ingest our marketing data into Databricks 10 times faster, allowing us to make data-driven decisions more quickly," said Ameya Narvekar, Data Insights Supervisor at NJM Insurance.
For more information about the CData Databricks Integration Accelerator, visit www.cdata.com/solutions/databricks.
About CData Software
CData Software is a leading provider of data access and connectivity solutions. Our self-service data products and connectivity solutions provide universal access to live data from hundreds of popular on-premises and cloud applications. Millions of users worldwide rely on CData to enable advanced analytics, boost cloud adoption, and create a more connected business. Consumable by any user, accessible within any application, and built for all enterprises, CData is redefining data-driven business. Learn more at www.cdata.com or reach a representative via email at info@cdata.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cdata-launches-databricks-integration-accelerator-to-simplify-and-accelerate-enterprise-data-integration-302477845.html
SOURCE CData Software
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
HyperStrong and Repono forge strategic collaboration to advance grid-scale battery energy storage projects in Europe
ZHUHAI, China, July 1, 2025 /PRNewswire/ -- HyperStrong, a global leading provider of battery energy storage system (BESS) solutions, and Repono AB, a European developer of large-scale energy storage projects, have formalised their strategic collaboration through a Partnering Agreement on 23 June, aimed at jointly advancing 1.4GWh grid-scale energy storage projects across Europe by 2027. The strategic partnership brings together complementary skills required for the rapid, large-scale deployment of electricity storage. Repono's project development expertise including site development, permitting, and grid interconnection, will be complemented by HyperStrong's full-scope system integration capabilities, including BESS solution delivery and associated lifecycle services. The collaboration reflects a shared commitment to accelerating the energy transition, while supporting Europe's ambition to scale local value chains and strengthen long-term industrial resilience. "We are excited to deepen our partnership with Repono to accelerate the deployment of safe, high-performance, and cost-effective energy storage infrastructure in Europe," said Mr. Pingyang Wang, Senior Vice President of HyperStrong International and President of EMEA Region. "This collaboration reflects our long-term commitment to the European market and our shared ambition to enable grid stability and energy transition in the region." Mr. Karim Nils Grueber, CEO of Repono, stated: "HyperStrong brings strong technical know-how and proven experience in delivering integrated BESS solutions which is complementary to Repono's extensive expertise in project development and more than 100,000 hours of BESS operations experience. We will lead with excellence in project design, permitting, and EPC coordination. Together, we aim to unlock the potential of grid-scale storage as a backbone for Europe's energy transition." Mr. Greger Landén, CTO of Repono, also expressed: "We have together with HyperStrong spent the last six months evaluating their technology and approach to the energy storage area. We have not only found a partner that is truly focused on performance and safety that aligns well with our values, but also a great team willing to discuss and develop our common approach in line with our needs for enabling the green transition in the European market." Under the agreement, both parties will engage in joint planning and project reviews, including technical and commercial alignment on identified pipeline projects. The agreement reflects a shared intent to leverage their complementary strengths for mutually beneficial success in future grid-scale projects. ENDS About HyperStrong Beijing HyperStrong Technology Co., Ltd. ("HyperStrong", is a global leading energy storage system (ESS) integrator and service provider. Founded in 2011, with more than 13 years of research and development, as well as experience garnered through more than 300 energy storage projects and more than 30GWh of deployment, HyperStrong offers a portfolio of ESS products and one-stop solutions for the full spectrum of utility-scale, commercial and industrial applications. Having built four smart manufacturing bases, three R&D centers, two testing labs and a global marketing center, HyperStrong empowers clients worldwide to achieve their energy transition and carbon neutrality goals. For more information about HyperStrong, visit: About Repono Repono AB is a Sweden-based energy infrastructure developer focusing on large-scale renewable and storage projects in the European market. Repono's expertise spans project origination, permitting, financing, and coordination of engineering, procurement, and construction (EPC) activities with a focus on leveraging from the operational and software experience within the company. For more information about Repono AB, visit: SOURCE Beijing HyperStrong Technology Co., Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 hours ago
- Yahoo
Monk Fruit Sweeteners Market to Reach $147.2 Million by 2032, Driven by Health Consciousness and Clean-Label Trends, Says Meticulous Research®
A new report by Meticulous Research® forecasts the global monk fruit sweeteners market to grow at a CAGR of 4.5% from 2025 to 2032 REDDING, Calif., June 30, 2025 /PRNewswire/ -- According to a comprehensive market research report titled "Monk Fruit Sweeteners Market Size, Share, Forecast, & Trends Analysis by Product Type (Monk Fruit Extract), Form (Solid), Category (Organic), Packaging Type, Application (Beverages, Food), Distribution Channel (B2B) - Global Forecast to 2032," the monk fruit sweeteners market is projected to reach $147.2 million by 2032, up from an estimated $107.9 million in 2025, growing at a steady CAGR of 4.5% during the forecast period. Market Segmentation Highlights: By Product Type: Monk fruit extracts dominate market with versatile applications in baked goods, beverages, and dietary supplements Monk fruit juice concentrates gaining adoption for natural beverage formulations Monk fruit infusions expanding in specialty health and wellness product categories Concentrated sweetness enabling manufacturers to use smaller quantities for desired sweetness levels To explore the complete report, visit: By Form: Solid form leads with 68.7% market share due to ease of handling, storage, and superior shelf life Liquid form gaining traction in beverage applications and processing convenience Solid formulations preferred for bakery, confectionery, and dry mix applications Versatility across multiple applications driving solid form market dominance By Category: Conventional segment maintaining larger market share with rising consumer demand for natural alternatives Organic segment projected to register highest CAGR with premium food product demand Certified organic products expanding in food & beverage industry applications Clean-label and sugar-free alternatives driving both conventional and organic segment growth By Application Analysis: Beverages segment accounts for 45.3% market share with health benefits and sugar-free product development Food applications expanding with natural sweetening solutions for dairy, bakery, and confectionery Nutrition & health supplements growing with zero-calorie and low glycemic index benefits Natural health and sports drinks with enhanced nutritional value supporting beverage segment growth Regional Market Leadership: North America dominates with 52.8% market share, driven by health consciousness and diabetes awareness Asia-Pacific expected to grow at highest CAGR of 5.1% with China as world's largest monk fruit producer Europe showing significant growth opportunities with clean-label product demand Latin America emerging as high-potential market with rising interest in natural sweeteners Key Market Drivers: Increasing health consciousness among consumers seeking natural, zero-calorie sugar alternatives Growing demand for organic and natural food & beverage products with clean-label attributes Rising prevalence of diabetes and obesity driving low-calorie sweetener adoption Product innovations including 100-250 times sweetness compared to traditional sugar Consumer preference for ingredients free from artificial additives and GMO components Clean-label trend with 78% of global consumers willing to pay premium for transparent products Emerging Market Opportunities: Increasing demand for monk fruit sweeteners in Europe and Latin America markets Rising consumer interest in natural sweeteners replacing artificial alternatives Growing demand for clean-label products emphasizing transparency and natural ingredients Premium positioning of organic monk fruit sweeteners in health-conscious consumer segments Integration with functional foods providing antioxidant effects and blood sugar regulation For more comprehensive insights, download the FREE report sample: Market Challenges: Stringent government regulations affecting product approval and market entry processes Higher prices compared to artificial sweeteners limiting mass market adoption Limited consumer awareness in emerging markets about monk fruit sweetener benefits Supply chain complexities with China as primary source of monk fruit production Insights from the Meticulous Research® Analyst Team: "The monk fruit sweeteners market represents a significant opportunity in the natural sweetener space, with diabetes cases projected to increase from 537 million to 783 million by 2045, driving demand for zero-calorie alternatives. Our research indicates Asia-Pacific will lead growth at 5.1% CAGR, leveraging China's production capabilities and traditional medicine heritage," said Mr. Uddhav Sable, Research Director at Meticulous Research®. Competitive Landscape: Leading market players include Monk Fruit Corp., Guilin Layn Natural Ingredients Corp., Archer-Daniels-Midland Company, GLG Life Tech Corporation, Apura Ingredients Inc., DSM-Firmenich AG, Hunan Huacheng Biotech Inc., Tate & Lyle PLC, Foodchem International Corporation, Whole Earth Sweetener Co. LLC, Lakanto, and Steviva Brands Inc., focusing on product innovation, organic offerings, and strategic partnerships with food & beverage manufacturers. Request a customized research analysis tailored to your specific requirements: About the Report: The 280-page report provides detailed insights into: Market Size & Forecast Analysis (2025–2032) Product Type Performance Benefits & Application Versatility Form Requirements & Packaging Solutions Regional Growth Opportunities & Consumer Behavior Analysis Competitive Landscape & Strategic Product Development Clean-Label Trends & Premium Product Positioning Immediate Delivery Available | Buy this Research Report: Related Reports: Natural Sweeteners Market Size, Share, Trends Analysis 2032 Fruit and Vegetable Ingredients Market Size, Share & Growth Report 2032 Organic Food Market by Size, Share, Forecasts, & Trends Analysis Functional Beverages Market Size, Share, Trends 2031 Juice Concentrates Market: Trends, & Future Growth Analysis About Meticulous Research®: We are a trusted research partner for leading businesses worldwide, empowering Fortune 500 organizations and emerging enterprises with market intelligence designed to drive revenue transformation and strategic growth since 2010. Our insights reveal future growth opportunities, equipping clients with a competitive edge through a versatile suite of research solutions—including syndicated reports, custom research, and direct analyst engagement. To find out more, visit or follow us on LinkedIn Contact: Mr. Khushal Bombe Meticulous Market Research Pvt. Ltd. 1267 Willis St, Ste 200 Redding, California, 96001, U.S. USA: +1-646-781-8004 Europe: +44-203-868-8738 APAC: +91 744-7780008 Email- sales@ Visit Our Website: Connect with us on LinkedIn- Content Source: Logo - View original content to download multimedia: SOURCE Meticulous Market Research Pvt. Ltd. Sign in to access your portfolio
Yahoo
16 hours ago
- Yahoo
Halozyme Therapeutics Added to Russell 1000® Index
SAN DIEGO, June 30, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that it has been added to the U.S. large-cap Russell 1000® Index, effective after market close on June 27th, as part of the 2025 FTSE Russell indexes annual reconstitution. The Russell 1000® Index includes approximately 1,000 of the largest U.S. securities based on market capitalization and is widely used by investors as a benchmark for the performance of large-cap stocks. "Joining the Russell 1000 Index is an important milestone that reflects our leadership in rapid large-volume subcutaneous drug delivery and our track record of durable top-and-bottom line growth," said Dr. Helen Torley, President and CEO of Halozyme. "The inclusion will help to expand our visibility among the investment community as we continue to execute our strategy and deliver sustainable growth and profitability well into the future." The Russell 1000® is managed by FTSE Russell, a global leader in index and analytics. Membership in the Russell 1000® Index, which remains in place for one year, is based on membership in the broad-market Russell 3000® Index. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals. Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc. Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility. For more information visit and connect with us on LinkedIn and Twitter. Safe Harbor Statement In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the future execution of Halozyme's strategy and delivery of future sustainable growth and profitability, the durability of Halozyme's top and bottom line growth, the possible activity, benefits and attributes of ENHANZE®, the possible method of action of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs, and statements concerning certain other potential benefits of ENHANZE® including facilitating more rapid delivery of injectable medications through subcutaneous delivery and potentially lowering the treatment burden for patients. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "expect," "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected results in the execution of Halozyme's strategy and unexpected future financial results and top and bottom line growth,. These and other factors that may result in differences are discussed in greater detail in Halozyme's most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission. Except as required by law, Halozyme undertakes no duty to update forward-looking statements to reflect events after the date of this release. Contacts: Tram BuiVP, Investor Relations and Corporate Communications609-333-7668tbui@ Sydney View original content to download multimedia: SOURCE Halozyme Therapeutics, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
